Dexcom Inc.
DexCom Reports Strong Q1 2026 Financial Results and Raises Guidance
Summary
DexCom, Inc. reported a 15% year-over-year increase in revenue to $1.192 billion for the first quarter of 2026, with GAAP operating income of $255.3 million and non-GAAP operating income of $264.4 million. The company expanded its product offerings and showcased clinical evidence at ATTD 2026. DexCom raised its fiscal year 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin, while reiterating guidance for Revenue and Non-GAAP Gross Profit Margin.
Profitelligence Alerts
Get alerts for DXCM
Be first to know when Dexcom Inc. files with the SEC.
Filing Categories
Advertisement
About Dexcom Inc.
Dexcom Inc. is a prominent player in the medical technology sector, specializing in continuous glucose monitoring (CGM) systems for diabetes management. The company's primary function is to develop and distribute innovative CGM devices that provide real-time glucose readings, allowing individuals with diabetes to make informed decisions about their health. Dexcom’s products play a critical role in healthcare by offering an alternative to traditional fingerstick testing, thus improving quality of life for many users. The company impacts several sectors, most notably within healthcare and technology, by integrating advanced data analytics and wireless technology into its monitoring systems. This not only aids individuals in managing their glucose levels but also supports healthcare providers in delivering better patient care through data-driven insights. In the financial market, Dexcom Inc. is recognized for its contributions to the growing field of digital health solutions. The company has established itself as a leader in its niche, continuously pushing the boundaries of technology to offer more precise and user-friendly glucose monitoring options. Founded in 1999 and headquartered in San Diego, California, Dexcom remains at the forefront of diabetes management solutions.
Official SEC Documents
Advertisement